Human Disease Glycomics/Proteome Initiative (HGPI)

The Alzheimer's disease neuroimaging initiative.

With increasing life expectancy in developed countries, the incidence of Alzheimer's disease (AD) and its socioeconomic impact are growing. Increasing knowledge of the mechanisms of AD facilitates the development of treatment strategies aimed at slowing down or preventing neuronal death. AD treatment trials using clinical outcome measures require long observation times and large patient samples...

Global initiative for chronic obstructive lung disease.

The Ontario Neurodegenerative Disease Research Initiative (ONDRI).

Because individuals develop dementia as a manifestation of neurodegenerative or neurovascular disorder, there is a need to develop reliable approaches to their identification. We are undertaking an observational study (Ontario Neurodegenerative Disease Research Initiative [ONDRI]) that includes genomics, neuroimaging, and assessments of cognition as well as language, speech, gait, retinal imagi...

NIH Launches Alzheimer's Disease Neuroimaging Initiative 3.

O n September 8, the National Institutes of Health (NIH) announced the launch of the next major phase of the long-running Alzheimer’s Disease Neuroimaging Initiative (ADNI), which functions as a consortium of medical and research centers investigating the causes, diagnosis, and progression of AD. ADNI3 has been funded by NIH at ;$40 million over the next 5 years, an amount that will be suppleme...

Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.

BACKGROUND Neuroimaging measures and chemical biomarkers may be important indices of clinical progression in normal aging and mild cognitive impairment (MCI) and need to be evaluated longitudinally. OBJECTIVE To characterize cross-sectionally and longitudinally clinical measures in normal controls, subjects with MCI, and subjects with mild Alzheimer disease (AD) to enable the assessment of th...